Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2025-12-27 @ 1:42 PM
Study NCT ID:
NCT06176560
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-19
First Post:
2023-12-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
Sponsor:
Faes Farma, S.A.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-03
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-08
Completion Date Type:
ESTIMATED
First Submit Date:
2023-12-04
First Submit QC Date:
None
Study First Post Date:
2023-12-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-16
Last Update Post Date:
2023-12-19
Last Update Post Date Type:
ACTUAL